Daptomycin - a novel antibiotic against Gram-positive pathogens (Q35925535)

11 August 2017

1 reference

title

Daptomycin - a novel antibiotic against Gram-positive pathogens (English)

1 reference

11 August 2017

main subject

gram-positive bacteria

0 references

(2S)-daptomycin

1 reference

ChEBI release 2020-05-28

2

Michael J Rybak

1 reference

11 August 2017

Kerry L LaPlante

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

2321-2331

1 reference

Resistance studies with daptomycin

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro bactericidal activity of daptomycin against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

The post-antibiotic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

In vivo pharmacodynamic activity of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Once-daily dosing in dogs optimizes daptomycin safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Effect of protein binding of daptomycin on MIC and antibacterial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Population pharmacokinetics of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.11.2321

10.1517/14656566.5.11.2321

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference